Epiendo Pharmaceuticals ehf.

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

3 Completed trials

2 Countries active

0 Unique IMPs

100% Results reported

Phase I (Other)

Phase I (Other): 2

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic obstructive pulmonary disease 2

All trials

2 total

A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adul… Ended

2024-516187-29-00 Phase I (Other) 1 country
An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the e… Ended

2023-506345-34-00 Phase I (Other) 1 country

Showing 1–2 of 2 trials

← All sponsors A–Z